Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide
Stig Lyngbæk, Per Winkel, Jens P Gøtze, Jens Kastrup, Christian Gluud, Hans Jørn Kolmos, Erik Kjøller, Gorm Boje Jensen, Jørgen Fischer Hansen, Per Hildebrandt, Jørgen Hilden, CLARICOR Trial Group
Dive into the research topics of 'Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide'. Together they form a unique fingerprint.